Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Preferred Shares (2023 - 2025)

Historic Preferred Shares for SAB Biotherapeutics (SABS) over the last 3 years, with Q3 2025 value amounting to $64.0.

  • SAB Biotherapeutics' Preferred Shares rose 118000.0% to $64.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $64.0, marking a year-over-year increase of 118000.0%. This contributed to the annual value of $5.0 for FY2024, which is 0.0% changed from last year.
  • SAB Biotherapeutics' Preferred Shares amounted to $64.0 in Q3 2025, which was up 118000.0% from $5.0 recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Preferred Shares ranged from a high of $64.0 in Q3 2025 and a low of $5.0 during Q4 2023
  • Moreover, its 3-year median value for Preferred Shares was $5.0 (2023), whereas its average is $12.38.
  • In the last 5 years, SAB Biotherapeutics' Preferred Shares changed by 0.0% in 2024 and then soared by 118000.0% in 2025.
  • SAB Biotherapeutics' Preferred Shares (Quarter) stood at $5.0 in 2023, then changed by 0.0% to $5.0 in 2024, then surged by 1180.0% to $64.0 in 2025.
  • Its last three reported values are $64.0 in Q3 2025, $5.0 for Q2 2025, and $5.0 during Q1 2025.